Haemonetics earnings release, May 7, 2026

Haemonetics Corp (HAE) · Form 8-K, Item 2.02 · Filed · SEC filing

Haemonetics Reports Fourth Quarter and Fiscal 2026 Results;

Provides Fiscal 2027 Guidance

Boston, MA, May 7, 2026

- Haemonetics Corporation (NYSE: HAE) reported financial results for its fourth quarter and fiscal 2026, which ended March 28, 2026:

__________

(1)

Excludes the impacts of currency fluctuation, the divestiture of the Whole Blood product line as of its completion in January 2025 and the exit of certain liquid solution products. The Company's acquisition of Vivasure Medical Limited ("Vivasure") in January 2026 had no impact on organic revenue growth rates and is not separately quantified.

(2)

In addition to the adjustments for organic revenue, further excludes the impact of fiscal 2025 disposable sales to CSL Plasma under its transitional U.S. supply agreement with the Company.

Chris Simon, Haemonetics’ CEO, stated: "Strong fourth quarter performance was largely driven by our core platforms, with outperformance in Plasma and Blood Management Technologies, and sequential improvement in Interventional Technologies. We successfully completed our four-year long-range plan, having built a more diversified, sustainable, and durable business and delivering impressive results against ambitious multi-year goals. With a strengthened competitive position and focus on disciplined execution, we have momentum for fiscal 2027 and beyond."

GAAP RESULTS

Fourth quarter fiscal 2026 revenue was

$346.4 million, up

4.8% co mpared with the fourth quarter of fiscal 2025. Business unit revenue and growth rates compared with the prior year period were as follows:¹

Gross margin was 57.2% in the fourth quarter of fiscal 2026, c ompared with 58.4% in the fourth quarter of fiscal 2025.

The primary driver of the decrease in the gross margin percentage was a charge taken for pre-acquisition inventory and inventory purchase commitments transferred from the Attune Medical acquisition that was deemed not recoverable, partially offset by decreased restructuring costs related to portfolio rationalization initiatives and decreased amortization of fair value inventory step-up.

Operating expenses in the fourth quarter of fiscal 2026 were

$221.2 million, an increase of $99.5 million, or 81.8%, when compared with the prior year period, driven by the impairment of intangible assets related to Attune Medical, partially offset by remeasurements of contingent consideration. Due to these charges, the Company had operating losses of $23.0 million and a (6.6)% operating margin in the fourth quarter of fiscal 2026, compared with operating income of $71.3 million and an operating margin of 21.6% in the fourth quarter of fiscal 2025. The income tax rates were

29.1% and

18.0% in the fourth quarters of fiscal 2026 and fiscal 2025, respectively. Additionally, due to the charges above, fourth quarter fiscal 2026 net loss and loss per diluted share were $20.1 million and $(0.44), respectively, compared with net income and earnings per diluted share of $58.0 million and $1.17, respectively, in the fourth quarter of fiscal 2025.

ADJUSTED RESULTS

Fourth quarter fiscal 2026 organic revenue growth was

4.5% and organic ex-CSL revenue growth was

8.6% compared with the same period of fiscal 2025. Year-over-year organic and organic ex-CSL growth rates by business unit were as follows:

Fourth quarter fiscal 2026 adjusted gross margin was 59.7%, down⁵⁰ basis points compared with the prior year period. The primary drivers for the decrease in adjusted gross margin percentage were less favorable mix and impacts from tariffs, partially offset by higher volume and pricing benefits.

Adjusted operating expenses were $122.2 million, up $5.5 million, or 4.7%, when compared with the prior year period.

The increase in adjusted operating expenses was largely driven by the acquisition of Vivasure, impacts from tariff and performance-based compensation as well as additional growth investments. Adjusted operati ng income for the fourth quarter of fiscal 2026 was $84.5 million, up $2.2 million or 2.6%, and adjusted operating margin was 24.4%, down 50 basis points, compared with the same period of fiscal 2025. The adjusted income tax rates were 24.8% and

22.2% in the fourth quarters of fiscal 2026 and fiscal 2025, respectively.

Fourth quarter fiscal 2026 adjusted net income was $59.7 million, down $1.8 million, or 3.0%, and adjusted earnings per diluted share was $1.29, up 4.0%, each when compared with the same period of fiscal 2025.

Financial statements

Income Statement

Fourth Quarter Fiscal 2026 Reported — mpared with the fourth quarter of fiscal 2025. Business unit revenue and growth rates compared with the prior year period were as follows: (in millions)

Fourth Quarter Fiscal 2026 ReportedFourth Quarter Fiscal 2026 Reported
Plasma130.32.8%
Blood Center56.40.7%
Hospital159.68.0%
Total net revenue346.44.8%

Income Statement

Fourth Quarter Fiscal 2026 — compared with the same period of fiscal 2025. Year-over-year organic and organic ex-CSL growth rates by business unit were as follows:

Fourth Quarter Fiscal 2026 – OrganicFourth Quarter Fiscal 2026 – Organic ex-CSL
Plasma1.8%12.7%
Blood Center5.5%5.5%
Hospital6.5%6.5%
Total net revenue4.5%8.6%

Income Statement

Haemonetics Corporation Financial Summary – Condensed Consolidated Statements of (Loss) Income (Unaudited) – Three Months Ended – 3/28/2026 – (Data and Shares in Thousands, Except Per Share Data)Haemonetics Corporation Financial Summary – Condensed Consolidated Statements of (Loss) Income (Unaudited) – Three Months Ended – 3/28/2026 – (Data and Shares in Thousands, Except Per Share Data)Haemonetics Corporation Financial Summary – Condensed Consolidated Statements of (Loss) Income (Unaudited) – Three Months Ended – 3/29/2025 – (Data and Shares in Thousands, Except Per Share Data)Haemonetics Corporation Financial Summary – Condensed Consolidated Statements of (Loss) Income (Unaudited) – Three Months Ended – 3/29/2025 – (Data and Shares in Thousands, Except Per Share Data)Haemonetics Corporation Financial Summary – Condensed Consolidated Statements of (Loss) Income (Unaudited) – Three Months Ended – Inc/(Dec) %Haemonetics Corporation Financial Summary – Condensed Consolidated Statements of (Loss) Income (Unaudited) – Twelve Months Ended – 3/28/2026 – (Data and Shares in Thousands, Except Per Share Data)Haemonetics Corporation Financial Summary – Condensed Consolidated Statements of (Loss) Income (Unaudited) – Twelve Months Ended – 3/28/2026 – (Data and Shares in Thousands, Except Per Share Data)Haemonetics Corporation Financial Summary – Condensed Consolidated Statements of (Loss) Income (Unaudited) – Twelve Months Ended – 3/29/2025 – (Data and Shares in Thousands, Except Per Share Data)Haemonetics Corporation Financial Summary – Condensed Consolidated Statements of (Loss) Income (Unaudited) – Twelve Months Ended – 3/29/2025 – (Data and Shares in Thousands, Except Per Share Data)Haemonetics Corporation Financial Summary – Condensed Consolidated Statements of (Loss) Income (Unaudited) – Twelve Months Ended – (Dec)/Inc %
Net revenues346,351330,5994.8%1,334,0271,360,824-2.0%
Cost of goods sold148,139137,5497.7%546,441611,866-10.7%
Gross profit198,212193,0502.7%787,586748,9585.2%
Research and development14,44615,914-9.2%59,76662,722-4.7%
Selling, general and administrative121,828115,3605.6%442,421436,7891.3%
Amortization of acquired intangible assets10,49111,296-7.1%43,99848,261-8.8%
Remeasurement of contingent consideration-2,774-20,855-86.7%-1,879-23,022-91.8%
Impairment of intangible assets77,246100.0%86,5462,3913519.7%
Total operating expenses221,237121,71581.8%630,852527,14119.7%
Operating (loss) income-23,02571,335-132.3%156,734221,817-29.3%
Interest and other expense, net-5,374-598798.7%-28,704-9,746194.5%
(Loss) income before (benefit) provision for income taxes-28,39970,737-140.1%128,030212,071-39.6%
(Benefit) provision for income taxes-8,25212,756-164.7%30,72244,392-30.8%
Net (loss) income-20,14757,981-134.7%97,308167,679-42.0%
Net (loss) income per share assuming dilution-0.441.17-137.6%2.053.31-38.1%
Weighted average number of shares:Basic46,22449,19347,17950,330
Weighted average number of shares:Diluted46,22449,47647,35450,730
Weighted average number of shares:Profit Margins:(Dec)/Inc %Inc/(Dec) %
Weighted average number of shares:Gross profit57.2%58.4%-1.2%59%55%4.0%
Weighted average number of shares:Research and development4.2%4.8%-0.6%4.5%4.6%-0.1%
Weighted average number of shares:Selling, general and administrative35.2%34.9%0.3%33.2%32.1%1.1%
Weighted average number of shares:Operating (loss) income-6.6%21.6%-28.2%11.7%16.3%-4.6%
Weighted average number of shares:(Loss) income before (benefit) provision for income taxes-8.2%21.4%-29.6%9.6%15.6%-6.0%
Weighted average number of shares:Net (loss) income-5.8%17.5%-23.3%7.3%12.3%-5.0%

Income Statement

Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the Hospital business unit.

Reconciliation of Adjusted Measures for Fourth Quarter of FY26 and FY25 (Unaudited) – Three Months Ended March 28, 2026: – Gross profitGross profitReconciliation of Adjusted Measures for Fourth Quarter of FY26 and FY25 (Unaudited) – Three Months Ended March 28, 2026: – Gross profitGross profitReconciliation of Adjusted Measures for Fourth Quarter of FY26 and FY25 (Unaudited) – Three Months Ended March 28, 2026: – Operating expensesOperating expensesReconciliation of Adjusted Measures for Fourth Quarter of FY26 and FY25 (Unaudited) – Three Months Ended March 28, 2026: – Operating expensesOperating expensesReconciliation of Adjusted Measures for Fourth Quarter of FY26 and FY25 (Unaudited) – Three Months Ended March 28, 2026: – Operating (loss) incomeOperating income (loss)Reconciliation of Adjusted Measures for Fourth Quarter of FY26 and FY25 (Unaudited) – Three Months Ended March 28, 2026: – Operating (loss) incomeOperating income (loss)Reconciliation of Adjusted Measures for Fourth Quarter of FY26 and FY25 (Unaudited) – Three Months Ended March 28, 2026: – Interest and other (expense) incomeInterest and other expenseReconciliation of Adjusted Measures for Fourth Quarter of FY26 and FY25 (Unaudited) – Three Months Ended March 28, 2026: – Interest and other (expense) incomeInterest and other expenseReconciliation of Adjusted Measures for Fourth Quarter of FY26 and FY25 (Unaudited) – Three Months Ended March 28, 2026: – (Benefit) provision for income taxesProvision (benefit) for income taxesReconciliation of Adjusted Measures for Fourth Quarter of FY26 and FY25 (Unaudited) – Three Months Ended March 28, 2026: – (Benefit) provision for income taxesProvision (benefit) for income taxesReconciliation of Adjusted Measures for Fourth Quarter of FY26 and FY25 (Unaudited) – Three Months Ended March 28, 2026: – Net (loss) incomeNet income (loss)Reconciliation of Adjusted Measures for Fourth Quarter of FY26 and FY25 (Unaudited) – Three Months Ended March 28, 2026: – Net (loss) incomeNet income (loss)Reconciliation of Adjusted Measures for Fourth Quarter of FY26 and FY25 (Unaudited) – Three Months Ended March 28, 2026: – (Loss) earnings per diluted share(1)(2)Earnings (loss) per diluted shareReconciliation of Adjusted Measures for Fourth Quarter of FY26 and FY25 (Unaudited) – Three Months Ended March 28, 2026: – (Loss) earnings per diluted share(1)(2)Earnings (loss) per diluted share
Reported198,212221,237-23,025-5,374-8,252-20,147-0.44
Amortization of acquired intangible assets-10,49110,4912,4718,0200.17
Acquisition, integration and transaction costs1,077-8,2969,3732942,2477,4200.16
Restructuring costs77-11919648148
Restructuring related costs-94-50-44-44
Digital transformation costs-5,0045,0041,2503,7540.08
Write down of certain assets-1721728686
Litigation-related charges-4434431073360.01
Impairment of intangible assets-77,24677,24618,98458,2621.26

Cash Flow

Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the Hospital business unit.

Condensed Consolidated Statements of Cash Flows (Unaudited) – Twelve Months Ended – March 28, 2026Condensed Consolidated Statements of Cash Flows (Unaudited) – Twelve Months Ended – March 29, 2025
Cash Flows from Operating Activities:Net income97,308167,679
Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization111,717115,586
Adjustments to reconcile net income to net cash provided by operating activities:Amortization of fair value inventory step-up5,81414,956
Adjustments to reconcile net income to net cash provided by operating activities:Share-based compensation expense33,82729,636
Adjustments to reconcile net income to net cash provided by operating activities:Impairment of intangible assets86,5462,391
Adjustments to reconcile net income to net cash provided by operating activities:Gain on repurchase of convertible senior notes, net-12,600
Adjustments to reconcile net income to net cash provided by operating activities:Gains on sales of property, plant and equipment-714-15,698
Adjustments to reconcile net income to net cash provided by operating activities:Deferred income taxes-26,471-5,219
Adjustments to reconcile net income to net cash provided by operating activities:Remeasurement of contingent consideration-1,879-23,022
Adjustments to reconcile net income to net cash provided by operating activities:Change in other non-cash operating activities10,7269,978
Change in operating assets and liabilitiesChange in accounts receivable, net-14,8816,956
Change in operating assets and liabilitiesChange in inventories, net47,361-64,704
Change in operating assets and liabilitiesChange in prepaid income taxes-4,534226
Change in operating assets and liabilitiesChange in other assets and other liabilities-35,028-25,232
Change in operating assets and liabilitiesChange in accounts payable and accrued expenses-16,571-19,208
Change in operating assets and liabilitiesNet cash provided by operating activities293,221181,725
Cash Flows from Investing Activities:Capital expenditures-32,780-39,278
Cash Flows from Investing Activities:Non-cash transfers from inventory to property, plant and equipment for Haemonetics equipment-51,891-21,112
Cash Flows from Investing Activities:Proceeds from divestiture and sale of assets43,291
Cash Flows from Investing Activities:Proceeds from sale of property, plant and equipment1,37523,253
Cash Flows from Investing Activities:Acquisitions-60,180-150,906
Cash Flows from Investing Activities:Other investments-36,071-17,143
Cash Flows from Investing Activities:Net cash used in investing activities-179,547-161,895
Cash Flows from Financing Activities:Repayments, net of borrowings-6,250447,312
Cash Flows from Financing Activities:Purchase of capped call related to convertible notes-88,200
Cash Flows from Financing Activities:Debt issuance costs-23,135
Cash Flows from Financing Activities:Share repurchase-175,000-225,000
Cash Flows from Financing Activities:Proceeds from employee stock programs7,8938,333
Cash Flows from Financing Activities:Cash used to net share settle employee equity awards-5,001-10,243
Cash Flows from Financing Activities:Other financing activities-102-249
Cash Flows from Financing Activities:Net cash (used in) provided by financing activities-178,460108,818
Cash Flows from Financing Activities:Effect of exchange rates on cash and cash equivalents3,463-685
Cash Flows from Financing Activities:Net Change in Cash and Cash Equivalents-61,323127,963
Cash Flows from Financing Activities:Cash and Cash Equivalents at Beginning of the Period306,763178,800
Cash Flows from Financing Activities:Cash and Cash Equivalents at End of Period245,440306,763
Free Cash Flow Reconciliation:Cash provided by operating activities293,221181,725
Free Cash Flow Reconciliation:Capital expenditures-32,780-39,278
Free Cash Flow Reconciliation:Additions to Haemonetics equipment-51,891-21,112
Free Cash Flow Reconciliation:Proceeds from sale of property, plant and equipment1,37523,253
Free Cash Flow Reconciliation:Free cash flow209,925144,588

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Haemonetics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.